公开(公告)号：US12076397B2

公开(公告)日：2024-09-03

申请号：US16300423

申请日：2017-05-10

申请人： The Regents of the University of Michigan ,  NanoBio Corporation

发明人： James R. Baker, Jr. ,  Douglas M. Smith ,  Susan Ciotti

IPC分类号： A61K39/395 ,  A61K9/00 ,  A61K9/107 ,  A61K38/38 ,  A61K39/12 ,  A61K39/145 ,  A61K39/39 ,  A61K47/10 ,  A61K47/18 ,  A61K47/26 ,  A61K47/34 ,  A61K39/00

CPC分类号： A61K39/39 ,  A61K9/0019 ,  A61K9/0043 ,  A61K9/107 ,  A61K38/38 ,  A61K39/12 ,  A61K39/145 ,  A61K47/10 ,  A61K47/186 ,  A61K47/26 ,  A61K47/34 ,  A61K2039/54 ,  A61K2039/55566

摘要： The present invention provides compositions comprising emulsion adjuvant and one or more active agents or substances formulated for infusion or injection into a subject (e.g., using a syringe and needle), as well as methods of formulating and using the same (e.g., as an injectable medicinal composition (e.g., a vaccine)). The emulsion adjuvant of an immunogenic composition of the invention in its preferred form comprises a cationic lipid containing a polar head group and a hydrophobic component (e.g., a dual chain hydrophobic group (e.g., the cationic surfactant dioctadecyl dimethyl ammonium chloride (DODAC) and dioctadecyl dimethyl ammonium bromine (DODAB))). Compositions of the invention comprising emulsion adjuvant and one or more active agents or substances formulated for administration via injection to a subject find use in treatment and/or prevention of infectious disease, cancer and/or allergy.

公开(公告)号：US20240245752A1

公开(公告)日：2024-07-25

申请号：US16538853

申请日：2019-08-13

申请人： TIANJIN PEGYLATT BIOTECHNOLOGY CO., LTD

发明人： Xuan Zhang

IPC分类号： A61K38/19 ,  A61K9/00 ,  A61K38/38 ,  A61K47/60 ,  A61P7/00

CPC分类号： A61K38/193 ,  A61K9/0019 ,  A61K38/38 ,  A61K47/60 ,  A61P7/00

摘要： The present invention provides a method to treat and/or prevent febrile neutropenia and Grade 3/4 neutropenia. The method comprises application a Declined mobilizing granulocyte colony-stimulating factor (De-mobilized G-CSF) at a selected time, and a controlled dosage depended on the severity of neutropenia. The present invention also provides evidences to identify the De-mobilized G-CSF and High-mobilized G-CSF, and a method for preparing the De-mobilized G-CSF.

公开(公告)号：US20240189432A1

公开(公告)日：2024-06-13

申请号：US18547504

申请日：2022-02-18

申请人： CHUO UNIVERSITY

发明人： Teruyuki KOMATSU ,  Wataru OKAMOTO ,  Tomone USUI

IPC分类号： A61K47/59 ,  A61K38/38 ,  A61K47/54 ,  A61K47/69 ,  A61P7/08

CPC分类号： A61K47/595 ,  A61K38/38 ,  A61K47/545 ,  A61K47/6925 ,  A61P7/08

摘要： It could be helpful to provide albumin to which a water-soluble polymer that has high biocompatibility and is easily prepared (synthesized) is bound; and an artificial plasma expander and a hemorrhagic shock resuscitation fluid that each contain the water-soluble polymer-bound albumin. The solution is a polyoxazoline-bound albumin (100) including an albumin (10) as a core and a polyoxazoline (20) as a shell, which is covalently bound to the albumin (10) via a cross-linker; and an artificial plasma expander and a hemorrhagic shock resuscitation fluid that each contain the polyoxazoline-bound albumin (100).

公开(公告)号：US20240115665A1

公开(公告)日：2024-04-11

申请号：US18543196

申请日：2023-12-18

申请人： Grifols Worldwide Operations Limited

发明人： Victor GRIFOLS ROURA ,  Antonio Manuel PAEZ REGADERA ,  Laura NUÑEZ DOMENECH

IPC分类号： A61K38/38 ,  A61P25/28

CPC分类号： A61K38/38 ,  A61P25/28

摘要： A method of treating a mild and moderate Alzheimer's Disease (AD), including conducting a low-volume plasma exchange (LVPE) to a subject suffering from the mild and moderate Alzheimer's Disease (AD); and administering an effective amount of a composition including human albumin at a concentration between 5% (w/v) and 25% (w/v) to the subject during the LVPE to replace with a subject's plasma. Use of low volume plasma exchange for the treatment of Alzheimer's Disease in early and middle stages. A composition including human albumin at a concentration between 5% (w/v) and 25% (w/v) for the treatment of mild and moderate Alzheimer's Disease (AD) by low-volume plasma exchange (LVPE).

公开(公告)号：US11918629B2

公开(公告)日：2024-03-05

申请号：US16710541

申请日：2019-12-11

申请人： Omrix Biopharmaceuticals Ltd.

发明人： Israel Nur ,  Elena Grimberg ,  Itai Podoler ,  Inbar Gahali-Sass ,  Erez Ilan ,  Ronen Eavri

IPC分类号： A61K38/00 ,  A61K9/08 ,  A61K33/06 ,  A61K38/36 ,  A61K38/37 ,  A61K38/38 ,  A61K38/48 ,  A61P7/04 ,  A61P41/00

CPC分类号： A61K38/363 ,  A61K9/08 ,  A61K33/06 ,  A61K38/366 ,  A61K38/37 ,  A61K38/38 ,  A61K38/4833 ,  A61P7/04 ,  A61P41/00 ,  C12Y304/21005

摘要： Provided herein are kits comprised of a first container including a solution of fibrinogen-containing component that includes fibrinogen at a concentration range of about 5 mg/ml to about 30 mg/ml, and having a total protein concentration range of about 15 mg/ml to about 40 mg/ml; and a second container that includes a solution of thrombin-containing component. Further provided are mixtures comprised of fibrinogen and thrombin, calcium ions, and albumin, the mixture being comprised of total protein in a range of about 2.5 mg/ml to about 30 mg/ml, fibrinogen in a range of about 50% to about 80% of total protein, and albumin in a range of more than 0.65 mg/ml to about 3 mg/ml. Further provided herein are methods for preventing or reducing tissue adhesion, and hydrogel materials made of fibrin.

公开(公告)号：US11850309B2

公开(公告)日：2023-12-26

申请号：US17001237

申请日：2020-08-24

申请人： The Brigham and Women's Hospital, Inc.

发明人： Omid Farokhzad ,  Jun Wu ,  Lili Zhao

IPC分类号： A61K9/51 ,  A61K9/50 ,  A61K9/00 ,  A61K47/60 ,  A61K47/59 ,  A61K47/64 ,  A61K47/69 ,  A61K38/38 ,  A61K38/28 ,  C08G81/00

CPC分类号： A61K9/5153 ,  A61K9/0019 ,  A61K9/5073 ,  A61K9/5078 ,  A61K9/5192 ,  A61K38/28 ,  A61K38/38 ,  A61K38/385 ,  A61K47/593 ,  A61K47/60 ,  A61K47/645 ,  A61K47/6931 ,  A61K47/6937 ,  C08G81/00

摘要： Cationic polymers are provided for delivering anionic active agents, preferably in the form or nanoparticles and other nanostructures. The polymer can be a polycation homopolymer or a copolymer containing a polycation block. The polycations and polycation containing polymers can contain dicarboxylic acid ester units and units of (α-amino acid)-α,ω-alkylene diester units. The nanoparticles can contain high loadings of anionic active agents, with sustained release of the active agents. Methods of making the polycations and polycation containing polymers are provided. Methods of making the nanoparticles and formulating them for administration to an individual in need thereof are also provided.

公开(公告)号：US20230372450A1

公开(公告)日：2023-11-23

申请号：US18030352

申请日：2021-10-05

申请人： LINNANE PHARMA AB

发明人： Catharina SVANBORG ,  Tran Thi HIEN

IPC分类号： A61K38/38 ,  A61K47/12 ,  A61K38/46 ,  A61P35/00

CPC分类号： A61K38/38 ,  A61K47/12 ,  A61K38/465 ,  A61P35/00 ,  C12Y301/01048

摘要： The invention provides a substantially water-free composition for use in preparing a biologically active complex, methods for preparing such compositions and to uses thereof.

公开(公告)号：US11779607B2

公开(公告)日：2023-10-10

申请号：US17827142

申请日：2022-05-27

申请人： Avotres, Inc.

发明人： Hong Jiang

IPC分类号： A61K35/17 ,  A61P37/02 ,  G01N33/50 ,  C12N5/0783 ,  C07K14/74 ,  C12N5/0784 ,  A61K31/10 ,  A61K35/15 ,  A61K38/17 ,  A61K38/38 ,  A61P37/04 ,  A61P17/06 ,  A61P25/28 ,  A61P37/06 ,  A61P19/02 ,  A61K47/20 ,  A61K47/42

CPC分类号： A61K35/17 ,  A61K31/10 ,  A61K35/15 ,  A61K38/1709 ,  A61K38/38 ,  A61K47/20 ,  A61K47/42 ,  A61P17/06 ,  A61P19/02 ,  A61P25/28 ,  A61P37/02 ,  A61P37/04 ,  A61P37/06 ,  C07K14/70539 ,  C12N5/0637 ,  C12N5/0639 ,  G01N33/505 ,  C12N2501/22 ,  C12N2501/2304

摘要： The present invention provides a composition comprising dendritic cells loaded with hHsp60sp, which dendritic cells are from a subject and have been fixed with paraformaldehyde (PFA). The subject may suffer from an autoimmune disease. Also provided are a method for preparing the composition; recombinant human cells comprising a heterologous gene encoding a fusion protein of HLA-E and hHsp60sp or B7sp, and expressing the fusion protein on the surface of the cells; a method for determining a percentage of maximum inhibition of testing the function of the HLA-E restricted CD8+ Treg cells from a subject, determining whether HLA-E restricted CD8+ Treg cells freshly isolated from a subject are defective, or determining whether defective HLA-E restricted CD8+ Treg cells from a subject are correctable; and a method for correcting defective HLA-E restricted CD8+ Treg cells, treating type 1 diabetes (T1D), or treating multiple sclerosis (MS).

公开(公告)号：US11660316B2

公开(公告)日：2023-05-30

申请号：US16951891

申请日：2020-11-18

申请人： Alkahest, Inc.

发明人： Viktoria Kheifets ,  Benson Lu

IPC分类号： A61K35/16 ,  A61P1/16 ,  A61K38/38 ,  A61K38/17

CPC分类号： A61K35/16 ,  A61K38/1722 ,  A61K38/38 ,  A61P1/16

摘要： Provided herein are methods of inducing liver regeneration in a subject diagnosed with a liver disorder. The method comprises administering a Plasma Protein Fraction (PPF) to the subject. In certain embodiments, the PPF comprises between 83% and 95% albumin in relation to total proteins. The PPF can be produced from plasma obtained from young individuals, for example, humans 40 years of age or younger.

公开(公告)号：US20190216825A1

公开(公告)日：2019-07-18

申请号：US16359602

申请日：2019-03-20

申请人： ORBIS BIOSCIENCES, INC.

发明人： Nathan Dormer ,  Cory Berkland

IPC分类号： A61K31/573 ,  A61K38/38 ,  A61K31/711 ,  A61K31/713 ,  A61K31/43 ,  A61K9/16 ,  A61K47/38 ,  A61K47/26 ,  A61K47/10 ,  A61K9/00 ,  A61K9/10 ,  A61K47/32

CPC分类号： A61K31/573 ,  A61K9/0019 ,  A61K9/0046 ,  A61K9/10 ,  A61K9/1635 ,  A61K9/1647 ,  A61K31/43 ,  A61K31/711 ,  A61K31/713 ,  A61K38/38 ,  A61K47/10 ,  A61K47/26 ,  A61K47/32 ,  A61K47/38

摘要： An extended-release drug delivery composition and method of administering the same is provided. The composition comprises microspheres loaded with a biologically-active agent and suspended in a soluble polymer capable of forming a film upon injection onto a biological surface.